Eli Lilly's triple agonist retatrutide delivered over 23% mean body weight reduction in Phase 3 while simultaneously cutting knee osteoarthritis pain by more than 75% � a dual benefit no prior obesity drug has demonstrated.
Retatrutide targets three metabolic receptors simultaneously: GIP, GLP-1, and glucagon. Where semaglutide acts on GLP-1 alone and tirzepatide adds GIP, retatrutides additional glucagon agonism drives increased energy expenditure and fat oxidation, pushing weight loss beyond what dual-agonist approaches achieve. Eli Lillys Phase 3 TRIUMPH-4 trial results reported up to 23.7% mean body weight reduction � approximately 27 kg / 60 lbs � at the 12 mg weekly dose versus just 4.6% for placebo.
Beyond the weight loss headline, TRIUMPH-4 produced a striking secondary finding: participants on retatrutide experienced up to 75.8% improvement in WOMAC knee pain scores, and more than one in eight patients on the highest dose reported complete freedom from knee pain at trial end. This combination of metabolic and musculoskeletal benefit positions retatrutide as a compelling option for the large overlap population of patients with both obesity and osteoarthritis.
Seven additional Phase 3 readouts across the TRIUMPH program are expected throughout 2026, covering cardiovascular outcomes, fatty liver disease (MASH), and diabetes indications. Eli Lilly has indicated an NDA filing is anticipated by Q4 2026. If approved, retatrutide would enter an increasingly crowded obesity drug market alongside tirzepatide and, potentially, CagriSema � intensifying what is shaping up to be one of the most competitive pharmaceutical launches in recent history.
Share this article
The Peptide Wizard
High-quality research peptides for lab use. Third-party tested with certificate of analysis available on every product.
Visit The Peptide WizardSponsored content. ThePBrief receives compensation. For research purposes only.